Pharma News

The U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. Heart failure occurs when the heart does not pump enough blood to support the body’s needs, and this type of heart failure happens when the heart’s main pumping chamber, the left ventricle, is weakened. With the approval, Farxiga is the first in this particular drug class, sodium-glucose co-transporter 2 (SGLT2) inhibitors, to be approved to treat adults with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction.

Necrotizing enterocolitis (NEC), a rare inflammatory bowel disease, primarily affects premature infants and is a leading cause of death in the smallest and sickest of these patients. The exact cause remains unclear, and there is no effective treatment. No test can definitively diagnose the devastating condition early, so infants with suspected NEC are carefully monitored and administered supportive care, such as IV fluids and nutrition, and antibiotics to fight infection caused by bacteria invading the gut wall. Surgery must be done to excise damaged intestinal tissue if the condition worsens.

Korean researchers have screened 48 FDA-approved drugs against SARS-CoV-2, and found that two, that are already FDA-approved for other illnesses, seem promising. The FDA approval for other uses would greatly reduce the time needed to gain FDA approval of use in COVID-19. The research is published in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.

Caption : Activating a receptor found on the surface of many normal and cancer tissues can not only stop pancreatic cancer from growing but may also make tumors more visible to the immune system and thus more susceptible to modern immunotherapy Credit : Penn Medicine

Activating the G protein-coupled estrogen receptor (GPER) - a receptor found on the surface of many normal and cancer tissues - has been shown to stop pancreatic cancer from growing, but may also make tumors more visible to the immune system and thus more susceptible to modern immunotherapy. Researchers at the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center observed the effects of GPER activation in human and mouse pancreatic cancer models and published their findings in Cellular and Molecular Gastroenterology and Hepatology today.

US Food and Drug Administration (USFDA) has classified the Alembic Pharmaceuticals General Oral Solid Formulation Facility located at Panelav as Voluntary Action Indicated (VAI).

AbbVie a research-based global biopharmaceutical company, and Allergan plc, a leading global pharmaceutical company, announced that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with AbbVie's pending acquisition of Allergan.

The state's premier educational institution ISF College of Pharmacy, Dr. G. D. Gupta, Director invented “Wearable Infection Protection Ring”. Dr. Gupta told during a special conversation that wearing this ring will help in avoiding Covid-19 pandemic disease.

Scientists from Jawaharlal Nehru Centre For Advanced Scientific Research (JNCASR) an autonomous institute under the Department of Science & Technology (DST), Govt. of India have modified the structure of Berberine, a natural and cheap product similar to curcumin, available commercially, into Ber-D to use as a Alzheimer’s inhibitor. Their research work has been published in the scientific journal iSceince. Alzheimer’s disease is the most prevalent neurodegenerative disorder and accounts for more than 70% of all dementia. The multifactorial nature of the disease attributed to multifaceted toxicity has made it difficult for researchers to develop effective medication.

Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from a randomized, controlled trial involving 1063 patients, which began on February 21. The trial (known as the Adaptive COVID-19 Treatment Trial, or ACTT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is the first clinical trial launched in the United States to evaluate an experimental treatment for COVID-19.